Testing the drug datopotamab deruxtecan for breast cancer that has spread to the brain
Official title: DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study is testing a drug called datopotamab deruxtecan in people whose breast cancer has spread to the brain.
Read our full plain-language summary
What the trial team says
The purpose of this study is to test the safety and effectiveness of the study drug datopotamab deruxtecan in participants with metastatic breast cancer that has spread to the brain. The name of the study drug used in this research study is: Datopotamab deruxtecan (a type of antibody-drug conjugate)
Key facts
- Registry number
- NCT06176261
- Stage of testing
- Phase 2
- Conditions studied
- Breast Cancer, Breast Cancer Female, Metastatic Triple-Negative Breast Carcinoma, ER Positive Breast Cancer, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, ER-negative Breast Cancer
Where it is running
This trial lists 3 sites.
-
Florida
- Miami Baptist Cancer Institute/ (Miami)
-
Massachusetts
- Dana-Farber Cancer Institute (Boston)
-
North Carolina
- Duke University Medical Center (Durham)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.